image credit: Freepik

Aspira Women’s Health and DFCI to form ovarian cancer diagnostic test

May 12, 2023

Aspira Women’s Health has entered an exclusive licensing deal with the Dana-Farber Cancer Institute (DFCI) to design and develop a new microRNA-based ovarian cancer diagnostic test.

The new test will use circulating microRNAs, either alone or along with proteins or other factors, for identifying ovarian cancer in women with adnexal masses.

It will be developed using a proprietary DFCI microRNA ovarian cancer signature along with the company’s proprietary AI/machine learning algorithms for evaluating the risk of ovarian cancer.

Read More on Medical Device Network